# MCE MedChemExpress

## **Product** Data Sheet

### **AZD1940**

Cat. No.: HY-119104 CAS No.: 881413-29-2 Molecular Formula:  $C_{20}H_{29}F_2N_3O_2S$ 

Molecular Weight: 413.52

Target: Cannabinoid Receptor


Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month



#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (241.83 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.4183 mL	12.0913 mL	24.1826 mL
	5 mM	0.4837 mL	2.4183 mL	4.8365 mL
	10 mM	0.2418 mL	1.2091 mL	2.4183 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.05 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.05 mM); Clear solution

#### **BIOLOGICAL ACTIVITY**

Description

AZD1940 is an orally active, high affinity cannabinoid CB1/CB2 receptor agonist with pK<sub>i</sub> values of 7.93 and 9.06 for human CB1R and CB2R, respectively. AZD1940 shows a robust analgesia action<sup>[1][2]</sup>.

IC<sub>50</sub> & Target hCB1-R hCB2-R 7.93 (pKi) 9.06 (pKi)

.55 (piti)

In Vitro AZD1940 binds with high affinity to human, rat and mouse CB1 and CB2 receptors and displays full agonism at both receptors in all three species<sup>[1][2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

When given orally to rats, AZD1940 produces a robust analgesia in different models of inflammatory and neuropathic pain<sup>[1]</sup>

 $For AZD1940, low \ brain \ uptake \ at \ an algesic \ doses \ has \ been \ demonstrated \ in \ both \ rats \ and \ primates \ [1].$ 

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Jarkko Kalliomäki, et al. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol. 2013 Mar;40(3):212-8.

[2]. Magnus Schou, et al. Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate. Nucl Med Biol. 2013 Apr;40(3):410-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA